Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$12.29 -0.17 (-1.36%)
As of 05/20/2022 09:37:53 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.